Sato Y, et al. - In previously untreated patients with histologically proven unresectable metastatic gastric cancer (n = 16), researchers assessed the recommended dose (RD) for a docetaxel/oxaliplatin/S-1 (DOS) regimen and report preliminarily results for its efficacy. On day 8, intravenous administration of docetaxel and oxaliplatin was carried out. On days 1–14, twice a day oral administration of S-1 was conducted. Every 3 weeks, each cycle was repeated. They assessed dose-limiting toxicities (DLTs) during the first treatment cycle. Level 1 (50/100/80 mg/m²), level 2 (50/130/80 mg/m²), and level 3 (60/130/80 mg/m²) were the three dose escalations of DOS that were used. In unresectable metastatic gastric cancer patients, DOS was found to be safe and tolerable. Moreover, encouraging preliminary efficacy with a high conversion rate was also documented.